Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 12, 2014, Pages 2015-2022

  Kwon, Mi ^a   Bautista, Guiomar ^b   Balsalobre, Pascual ^a   Sánchez Ortega, Isabel ^c   Serrano, David ^a   Anguita, Javier ^a   Buño, Ismael ^a   Fores, Rafael ^b   Regidor, Carmen ^b   García Marco, José A ^b   Vilches, Carlos ^b   de Pablo, Rosario ^b   Fernández, Manuel N ^d   Gayoso, Jorge ^a   Duarte, Rafael ^c   Díez Martín, José Luis ^a   Cabrera, Rafael ^b,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alternative donor; Cord blood transplantation; Haploidentical

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HLA ANTIGEN; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; CD34 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; APLASTIC ANEMIA; ARTICLE; BODY WEIGHT; BONE MARROW DEPRESSION; CANCER PATIENT; CD34 SELECTION; CELL COUNT; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HUMAN CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NEUTROPHIL; ORGAN DONOR; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; SURGICAL RISK; THROMBOCYTE COUNT; WHOLE BODY RADIATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MORTALITY; STEM CELL; SURVIVAL RATE; TIME;

ADULT; ANTIGENS, CD34; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; STEM CELLS; SURVIVAL RATE; TIME FACTORS;

EID: 84912079621     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.08.024     Document Type: Article

References (36)

1. Ballen K.K., Gluckman E., Broxmeyer H.E. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013, 122:491-498.
2. Ballen K.K., Barker J.N. Has umbilical cord blood transplantation for AML become mainstream?. Curr Opin Hematol 2013, 20:144-149.
3. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. NEngl J Med 2004, 351:2265-2275.
4. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
5. + cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 2010, 16:500-508.
6. Szabolcs P., Park K.-D., Reese M., et al. Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp Hematol 2003, 31:708-714.
7. Takanashi M., Atsuta Y., Fujiwara K., et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010, 116:2839-2846.
8. Cutler C., Kim H.T., Sun L., et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011, 118:6691-6697.
9. Rocha V., Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009, 147:262-274. Eurocord-Netcord registry and European Blood and Marrow Transplant group.
10. Rocha V., Broxmeyer H.E. New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant 2010, 16(1 Suppl):S126-132.
11. Cairo M.S., Wagner E.L., Fraser J., et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion 2005, 45:856-866.
12. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
13. Norkin M., Lazarus H.M., Wingard J.R. Umbilical cord blood graft enhancement strategies: has the time come to move these into the clinic?. Bone Marrow Transplant 2013, 48:884-889.
14. Frassoni F., Gualandi F., Podestà M., et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008, 9:831-839.
15. Fernández M.N., Regidor C., Cabrera R., et al. Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol 2003, 31:535-544.
16. Bautista G., Cabrera J.R., Regidor C., et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant 2009, 43:365-373.
17. Magro E., Regidor C., Cabrera R., et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica 2006, 91:640-648.
18. Liu H., Rich E.S., Godley L., et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011, 118:6438-6445.
19. Kwon M., Balsalobre P., Serrano D., et al. Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant 2013, 19:143-149.
20. Buño I., Nava P., Simón A., et al. Acomparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica 2005, 90:1373-1379.
21. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
22. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. NEngl J Med 1998, 339:1565-1577.
23. Kwon M., Martínez-Laperche C., Balsalobre P., et al. Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells. Bone Marrow Transplant 2014, 49:212-218.
24. Avery S., Shi W., Lubin M., et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011, 117:3277-3285. quiz 3478.
25. Page K.M., Zhang L., Mendizabal A., et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant 2011, 17:1362-1374.
26. Sanz J., Boluda J.C.H., Martín C., et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012, 47:1287-1293.
27. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
28. Mohty M., Gaugler B. Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. Best Pract Res Clin Haematol 2010, 23:275-282.
29. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
30. Scaradavou A. HLA-mismatched, noninherited maternal antigen-matched unrelated cord blood transplantations have superior survival: how HLA typing the cord blood donor's mother can move the field forward. Biol Blood Marrow Transplant 2012, 18:1773-1775.
31. Barker J.N., Byam C.E., Kernan N.A., et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant 2010, 16:1541-1548.
32. Eapen M., Klein J.P., Sanz G.F., et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011, 12:1214-1221.
33. Van Besien K., Liu H., Jain N., et al. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant 2013, 19:682-691.
34. Delaney C., Ratajczak M.Z., Laughlin M.J. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol 2010, 3:273-283.
35. Martín-Donaire T., Rico M., Bautista G., et al. Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor. Bone Marrow Transplant 2009, 44:213-225.
36. Fernández M.N. Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors. Br J Haematol 2009, 147:161-176.